drugset / Trial / NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1
Recruiting
12 enrolled
UNC Lineberger Comprehensive Cancer Center
Exelixis · collabRegeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
Timeline
- Start
- 2025-06-03
- Primary completion
- 2028-03-31
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Zanzalintinib | Small molecule | 60 mg | Oral |